To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for
treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we …

Diabetes is a highly prevalent metabolic disease that has emerged as a global challenge
due to its increasing prevalence and lack of sustainable treatment. Diabetic kidney disease …

Background We conducted a systematic review and meta-analysis of the cardiovascular,
kidney, and safety outcomes of sodium-glucose cotransporter 2 inhibitors (SGLT2i) among …

Chronic kidney disease due to diabetes, or diabetic kidney disease (DKD), is a worldwide
leading cause of chronic kidney disease and kidney failure and an increasingly important …

Background Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduce kidney disease
progression and mortality in patients with chronic kidney disease (CKD), regardless of …

Chronic kidney disease (CKD) is associated with increased morbidity and mortality,
especially from cardiovascular (CV) causes, and especially in people with diabetes mellitus …

Background Monotherapy to treat obesity‐associated liver insult is limited. Objectives In diet‐
induced obese mice showing metabolic dysfunction‐associated steatotic liver disease …

Introduction The management of chronic diabetes mellitus and its complications demands
customized glycaemia control strategies. Polypharmacy is prevalent among people with …

Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease. Along with the
increasing prevalence of diabetes, DKD is expected to affect a higher number of patients …

Background Chronic kidney disease (CKD), a serious complication of type 2 diabetes (T2D)
increases the comorbid risk of cardiovascular disease (CVD) and end-stage kidney disease …